Publications by authors named "Emiko Tsugami"
Article Synopsis
- The study examined the effectiveness of a combination therapy of insulin degludec and liraglutide (IDegLira) in managing type 2 diabetes among Japanese patients, particularly focusing on liver health as assessed by the Fibrosis-4 index (FIB-4).
- In a group of 113 patients over 6 months, both those previously treated with glucagon-like peptide-1 receptor agonists (GLP-1RA) and those who were not showed significant reductions in glycated hemoglobin, indicating improved blood sugar control.
- While weight decreased in the GLP-1RA-naïve group, it slightly increased in the GLP-1RA-treated group, and FIB-4 levels improved
Purpose: The factors associated with the renal prognosis over six months after the initiation of empagliflozin were compared between the non-elderly and elderly Japanese patients with type 2 diabetes.
Patients And Methods: In total, 132 patients treated with empagliflozin (10 mg, once daily) were studied as the safety analysis set. One hundred ten subjects whose medications were not changed during the observation period were investigated as the full analysis set to assess the effectiveness.
Article Synopsis
- The study aimed to assess how switching from daily DPP-4 inhibitors to weekly trelagliptin affects patient satisfaction, medication adherence, and unused medication in type 2 diabetes patients.
- A total of 79 patients participated after excluding those who didn't want to switch; their satisfaction and adherence were measured at baseline and 3 months post-switch.
- Results showed no change in HbA1c levels, but significant improvements in treatment satisfaction, perception of medication, adherence, and a reduction in unused drugs after the switch.
Article Synopsis
- - The study compared the effects of switching type 2 diabetes patients from insulin glargine U100 to either an IGlar biosimilar or IGlar U300 over six months, focusing on changes in HbA1c levels and body weight.
- - Results showed no significant differences in HbA1c levels or body weight between the two groups, with IGlar U300 users experiencing a notable decrease in hypoglycemia occurrences compared to before the switch.
- - Overall, both IGlar biosimilar and IGlar U300 produced similar outcomes in managing diabetes, suggesting that IGlar biosimilar is a good option, especially for patients who are less prone to hypoglycemia.
Article Synopsis
- - The study explored changes in clinical characteristics and medication prescriptions among type 2 diabetic patients experiencing severe hypoglycemia from 2008 to 2013, revealing significant shifts in medication types used.
- - An increase in patients using insulin, biguanides, and other newer medications was noted, while the use of sulfonylureas dropped significantly. Additionally, the frequency of medication errors contributing to hypoglycemia rose over the same period.
- - The findings highlight a rise in polypharmacy among insulin users and emphasize the need for effective education on medication management to prevent severe hypoglycemia in these patients.
Background: We investigated 1) the frequency of hypertension in patients with type 2 diabetes graded by the new classification of chronic kidney disease (CKD) reported by the Kidney Disease: Improving Global Outcomes (KDIGO) and 2) the number of antihypertensive agents needed to achieve treatment goals using a prospective observational study.
Methods: A population of 2018 patients with type 2 diabetes mellitus was recruited for the study. The CKD stage was classified according to the eGFR and the urinary albumin excretion levels.